<--- Back to Details
First PageDocument Content
Arthritis / Rheumatoid arthritis / Food and Drug Administration / Joint replacement / Arthroplasty / Medical device / Federal Food /  Drug /  and Cosmetic Act / Arthrodesis / Medicine / Orthopedic surgery / Ankle replacement
Date: 2012-04-20 11:03:31
Arthritis
Rheumatoid arthritis
Food and Drug Administration
Joint replacement
Arthroplasty
Medical device
Federal Food
Drug
and Cosmetic Act
Arthrodesis
Medicine
Orthopedic surgery
Ankle replacement

Microsoft Word - 1-NCHC Total Ankle Replacement Policy-termination[removed]Redo.doc

Add to Reading List

Source URL: www.ncdhhs.gov

Download Document from Source Website

File Size: 96,06 KB

Share Document on Facebook

Similar Documents

Evolving New Practices in Hip & Knee Arthroplasty: It Takes A Team! CCHSE National Healthcare Leadership Conference June 11-12, 2007 Toronto

DocID: 1tdNL - View Document

□ I hereby indicate that these comorbidities may have a detrimental effect on this arthroplasty. Present Clinical Risk Factor ICD10 Code Descriptor Morbid obesity BMI >40 E66.09 Morbid (severe) obesity due to excess

DocID: 1sWjL - View Document

□ I hereby indicate that these comorbidities may have a detrimental effect on this arthroplasty. Present ICD10 Clinical Risk Factor Code

DocID: 1sSMY - View Document

Effect of Obesity on Efficacy of Medical Thromboprophylaxis After Total Knee Arthroplasty- A Case Control Study Banafsheh Sadeghi MD PhD -- UC Davis Richard H. White MD --- UC Davis Patrick S. Romano MD MPH--UC Davis

DocID: 1sJl8 - View Document

Total Hip Arthroplasty Protocol POD #0 Post operative check Ted hose and SCDs on patients bilateral lower extremities POD #1 AM Labs, or post transfusion H/H, platelets

DocID: 1spTC - View Document